<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398173</url>
  </required_header>
  <id_info>
    <org_study_id>ProBiopsy-RM19</org_study_id>
    <nct_id>NCT04398173</nct_id>
  </id_info>
  <brief_title>Detection Rate of Prostate Cancer in Men Undergoing MRI</brief_title>
  <official_title>A Retrospective Observational Study to Assess Prostate Cancer Detection Rate in Men Undergoing Magnetic Resonance Imaging: Comparison Between Subjects With Previous Negative Biopsy and Biopsy Naive Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione del Piemonte per l'Oncologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione del Piemonte per l'Oncologia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess prostate cancer (PCa) detection rate in men undergoing magnetic resonance imaging&#xD;
      (MRI) before planning prostate biopsy. Results will be stratified considering men&#xD;
      with/without previous negative prostate biopsy.&#xD;
&#xD;
      Secondary objective will be to compute the negative predictive value of MRI in subject with&#xD;
      no lesion detected at imaging or no cancer confirmed at biopsy, considering a follow-up of at&#xD;
      least 2 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a retrospective observational study, with the aim to compare two cohorts of&#xD;
      patients with suspicion of PCa who will undergo MRI. Group A is composed by patients with&#xD;
      previous negative biopsy, while group B is composed by men with no previous negative prostate&#xD;
      biopsy.&#xD;
&#xD;
      To reach primary aim, men with positive MRI (clinically significant lesions with PI-RADS&#xD;
      score &gt;= 3) and biopsy data will be considered.&#xD;
&#xD;
      In men with negative MRI (clinically insignificant lesions or regions classified as PI-RADS 2&#xD;
      at MRI), follow-up with PSA data and repeated MRI and/or biopsy will be considered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2014</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PCa detection rate</measure>
    <time_frame>24 months</time_frame>
    <description>Number of men with positive prostate biopsy over the number of men with a positive MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of MRI</measure>
    <time_frame>24 months</time_frame>
    <description>Number of men with negative MRI or positive MRI but negative biopsy who are confirmed as negative for PCa during the follow-up over the total number of subjects considered during the follow-up</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>Group A (previous negative biopsy)</arm_group_label>
    <description>Men with clinical suspicion of PCa, previous negative prostate biopsy who underwent prostate MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (biopsy naive)</arm_group_label>
    <description>Men with clinical suspicion of PCa, no previous negative prostate biopsy who underwent prostate MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>multiparametric MRI</intervention_name>
    <description>T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging</description>
    <arm_group_label>Group A (previous negative biopsy)</arm_group_label>
    <arm_group_label>Group B (biopsy naive)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men with clinical suspicion of PCa, eligible for prostate biopsy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 50 and life expectancy greater than 10 years&#xD;
&#xD;
          -  PSA values persistently greater than 4 ng/ml&#xD;
&#xD;
          -  multiparametric MRI of the prostate between nov-2014 and nov-2016&#xD;
&#xD;
          -  MRI with endorectal coil&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous history of PCa&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia - Candiolo Cancer Institute</name>
      <address>
        <city>Candiolo</city>
        <state>Turin</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>prostate biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

